Sintx Technologies, Inc. SINT

Company Overview

Sintx Technologies, Inc. is a U.S.-based advanced ceramics company focused on the development, manufacturing, and commercialization of silicon nitride-based materials and components for medical, industrial, and technology applications. The company operates primarily within the advanced materials, biomedical device materials, and technical ceramics industries. Its core competency is the production and engineering of silicon nitride ceramics, a material known for high strength, wear resistance, biocompatibility, and antimicrobial characteristics. Sintx historically derived revenue from spinal implant materials and medical device-related products, while also pursuing broader industrial applications for its ceramic technologies.

The company’s principal business lines include advanced ceramic manufacturing, biomaterial development, contract manufacturing, and intellectual property licensing related to silicon nitride technologies. Sintx serves medical device manufacturers, industrial equipment producers, and research-oriented customers seeking specialty ceramic applications. The company traces its origins to Amedica Corporation, which was founded to commercialize silicon nitride in spinal implants and orthopedic applications. Following restructuring efforts and strategic repositioning, the company rebranded as Sintx Technologies to emphasize diversified industrial and technological uses of silicon nitride beyond spinal implants.

Business Operations

Sintx generates revenue through the manufacture and sale of silicon nitride materials, precision ceramic components, biomedical products, and research collaborations. The company’s operations are centered around advanced ceramic processing capabilities, including powder synthesis, component fabrication, machining, and finishing. Its core operating activities historically included the spinal implant segment, though the company has increasingly focused on broader technical ceramics opportunities. Sintx controls proprietary silicon nitride formulations, manufacturing processes, and related intellectual property developed over years of biomedical research and production.

Operations are primarily based in the United States, with manufacturing and corporate activities centered in Utah. The company has pursued partnerships and development arrangements involving medical technology firms, research institutions, and industrial customers seeking high-performance ceramic solutions. Sintx has also emphasized contract development and manufacturing opportunities leveraging its expertise in advanced ceramics. Public filings and investor materials indicate continued efforts to expand applications into aerospace, defense, semiconductors, filtration, and energy-related markets where silicon nitride’s durability and thermal properties may offer advantages.

Strategic Position & Investments

Sintx’s strategic direction has centered on repositioning the company from a spinal implant-focused enterprise into a diversified advanced ceramics platform. Growth initiatives have included expanding industrial applications for silicon nitride, commercializing antimicrobial ceramic technologies, and pursuing licensing or collaborative development opportunities. The company has invested in research related to additive manufacturing, advanced coatings, and next-generation ceramic technologies intended for both medical and non-medical applications.

The company has also pursued acquisitions and strategic transactions historically tied to medical device technologies and manufacturing capabilities, although its more recent focus has emphasized capital efficiency and targeted commercialization efforts. Sintx maintains a portfolio of patents and proprietary technologies related to silicon nitride biomaterials and ceramic processing. Public disclosures indicate interest in emerging sectors such as semiconductor manufacturing components, ballistic protection materials, renewable energy systems, and aerospace applications. Some anticipated commercialization pathways remain developmental, and certain market expansion initiatives have not yet achieved large-scale revenue contribution based on available public filings.

Geographic Footprint

Sintx’s headquarters and primary operational facilities are located in Utah, United States, where the company conducts manufacturing, research, engineering, and administrative functions. The company’s historical customer base has been concentrated in the United States, particularly within the medical device sector, though it has also pursued commercial relationships internationally through distributors, development agreements, and export activity.

The company’s market ambitions extend into North America, Europe, and parts of Asia, particularly in industries requiring advanced engineered ceramics. While Sintx does not currently operate a large multinational manufacturing footprint comparable to major global materials companies, it has sought international relevance through intellectual property development, technical collaborations, and participation in global medical and industrial supply chains. Publicly available information indicates that the majority of operational control and revenue generation remains U.S.-centered.

Leadership & Governance

Sintx Technologies has undergone multiple leadership transitions during its evolution from a spinal implant company into a broader advanced ceramics business. Governance and strategic direction have emphasized commercialization of proprietary silicon nitride technologies, operational restructuring, and diversification into industrial applications. Company leadership has consistently highlighted innovation in biomaterials and engineered ceramics as central to long-term strategy.

Key executives and directors identified in recent public filings include:

• Eric K. Olson – Chief Executive Officer
• Richard “Rick” J. Tuntland – Chief Financial Officer
• B. Sonny Bal – Chairman of the Board
• Barbara A. Christy – Board Member
• Mark J. Rothermel – Board Member

Leadership communications in SEC filings and investor presentations have emphasized intellectual property monetization, strategic partnerships, manufacturing optimization, and expansion into higher-growth advanced materials markets. Certain executive appointments and board compositions have changed over time, and investors should consult the company’s most recent Form 10-K, Form 10-Q, and proxy filings for current governance details.